Cadrenal Therapeutics, Inc.
CVKD- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001937993
No open-market purchases or sales by Cadrenal Therapeutics, Inc. insiders were filed in the last 90 days; 19 institutions reported holding it in 13F filings for Q2 2026, worth $379.6K in total; no superinvestor holds it.
Q2 2025 vs. Q1 2025
How the institutions holding Cadrenal Therapeutics, Inc. changed between Q1 2025 and Q2 2025.
All holders in Q2 2025All holders in Q1 2025
| Measure | Q1 2025 | Q2 2025 | Change |
|---|---|---|---|
| Holders | 16 | 17 | +1 |
| Shares | 69.4K | 68.4K | −957 (−1.4%) |
| Value | $1.22M | $823.9K | −$398.9K (−32.6%) |
New holders (4)
Institutions that held Cadrenal Therapeutics, Inc. at the end of Q2 2025 but not at the end of Q1 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| BlackRock, Inc. | 3,282 | $39.5K | 0.00% |
| Raymond James Financial Inc | 1,917 | $23.1K | 0.00% |
| Tower Research Capital LLC (TRC) | 136 | $1.64K | 0.00% |
| Harbour Investments, Inc. | 100 | $1.21K | 0.00% |
Sold out (3)
Institutions that held Cadrenal Therapeutics, Inc. at the end of Q1 2025 and filed for Q2 2025 without it.
| Institution | Shares, Q1 2025 | Value, Q1 2025 |
|---|---|---|
| JPMorgan Chase & Co | 100 | $1.76K |
| UMA Financial Services, Inc. | 52 | $917 |
| Frazier Financial Advisors, LLC | 10 | $177 |